Prevalence of Hyperuricemia Among Chinese Adults: Findings From Two Nationally Representative Cross-Sectional Surveys in 2015–16 and 2018–19
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Objective: To determine the nationwide prevalence of hyperuricemia in China and evaluate its trends and associated risk factors. Methods: Using a multi-stage, stratified, cluster-randomized sampling design, two cross-sectional surveys (representative of national and provincial information) were conducted in 31 provinces (autonomous regions and municipalities) in mainland China, with 166, 861 Chinese adults in 2015–16 and 168, 351 in 2018–19. Serum uric acid (SUA) levels of all participants were measured after a >10-hour overnight fast. Hyperuricemia (HUA) was defined when SUA was >420 μmol/L. Prevalence estimates were weighted to represent the total population considering the complex sampling design. Multivariable logistic regression models was used to estimate factors associated with HUA. Results: The overall hyperuricemia prevalence in the Chinese adult population was 11.1% (95% confidence interval 10.3% to 11.8%) in 2015–16 and 14.0% (13.1% to 14.8%) in 2018–19; an alarming rise was observed in the three years. Hyperuricemia was more common in men with 19.3% (17.9% to 20.7%) in 2015–16 and 24.4% (23.0% to 25.8%) in 2018–19, although the prevalence also escalated from 2.8% (2.5% to 3.0%) in 2015–16 to 3.6% (3.2% to 4.0%) in 2018–19 in women. The hyperuricemia risk factors include the urban culture, settlement in the East, Zhuang descent, high education, heavy or frequent beer drinking, high red meat intake, physical inactivity, high body mass index, central obesity, hypertension, hyperlipidemia, and low glomerular filtration rate. Conclusion: The estimated hyperuricemia prevalence among Chinese adults was 14.0% in 2018-19; significant escalating trends were observed between 2015-16 and 2018-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors
Dehlin, M., Jacobsson, L., & Roddy, E. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0441-1 · Cited by 1,370
Chen‐Xu, M., Yokose, C., Rai, S. K., Pillinger, M. H., & Choi, H. K. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40807 · Cited by 1,072
Choi, H. K., Mount, D. B., & Reginato, A. M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-7-200510040-00009 · Cited by 942
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41247 · Cited by 810
Self-citation[2010 Chinese guidelines for the management of hypertension].
Liu, L. (2011) · PubMed · Cited by 698
2016 Chinese guidelines for the management of dyslipidemia in adults.
(2018) · PubMed · doi:10.11909/j.issn.1671-5411.2018.01.011 · Cited by 457
Liu, S., Wu, X., Lopez, A. D., Wang, L., Cai, Y., Page, A., Yin, P., Liu, Y., Li, Y., Liu, J., et al. (2016) · Bulletin of the World Health Organization · doi:10.2471/blt.15.153148 · Cited by 395
Self-citation[2016 Chinese guideline for the management of dyslipidemia in adults].
(2016) · PubMed · doi:10.3760/cma.j.issn.0253-3758.2016.10.005 · Cited by 361
Virdis, A., Masi, S., Casiglia, E., Tikhonoff, V., Cicero, A. F. G., Ungar, A., Rivasi, G., Salvetti, M., Barbagallo, C. M., Bombelli, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.13643 · Cited by 279
Uric Acid as a Target of Therapy in CKD
Jalal, D. I., Chonchol, M., Chen, W., & Targher, G. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.021 · Cited by 268
Miao, Z., Li, C., Chen, Y., Zhao, S., Wang, Y., Wang, Z., Chen, X., Xu, F., Wang, F., Sun, R., et al. (2008) · PubMed · Cited by 247
Self-citationLiu, H., Zhang, X.-M., Wang, Y.-L., & Liu, B.-C. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0082-z · Cited by 219
Self-citationEbrahimpour-koujan, S., Saneei, P., Larijani, B., & Esmaillzadeh, A. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1503155 · Cited by 173
Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.216416 · Cited by 172
Relationship between lifestyle choices and hyperuricemia in Chinese men and women
Liu, L., Lou, S., Xu, K., Meng, Z., Zhang, Q., & Song, K. (2012) · Clinical Rheumatology · doi:10.1007/s10067-012-2108-z · Cited by 105
Liu, F., Du, G., Song, N., Ma, Y.-T., Li, X., Gao, X., & Yang, Y. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01211-z · Cited by 90
Koto, R., Nakajima, A., Horiuchi, H., & Yamanaka, H. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1784556 · Cited by 81
Data Resource Profile: China Chronic Disease and Risk Factor Surveillance (CCDRFS)
Zhang, M., Wang, L., Wu, J., Huang, Z., Zhao, Z., Zhang, X., Li, C., Zhou, M., & Wang, L. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab255 · Cited by 73
Self-citationChallenges of conducting a trial of uric-acid-lowering therapy in CKD
Badve, S. V., Brown, F. G., Hawley, C. M., Johnson, D. W., Kanellis, J., Rangan, G. K., & Perkovic, V. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.186 · Cited by 61
Cho, S. K., Winkler, C. A., Lee, S., Chang, Y., & Ryu, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030296 · Cited by 58
Chiang, K.-M., Tsay, Y., Ng, T.-C. V., Yang, H., Huang, Y., Chen, C., & Pan, W. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081202 · Cited by 53
Present and Future of Digital Health in Diabetes and Metabolic Disease
Rhee, S. Y., Kim, C., Shin, D. W., & Steinhubl, S. R. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0088 · Cited by 47
Puddu, P. E., Bilancio, G., Terradura-Vagnarelli, O., Lombardi, C., Mancini, M., Zanchetti, A., & Menotti, A. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.029 · Cited by 46
Stamp, L. K., FRAMPTON, C. M. A., Drake, J. M., Doughty, R. N., Troughton, R. W., & Richards, M. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41007 · Cited by 34
Otaki, Y., Watanabe, T., Konta, T., Watanabe, M., Asahi, K., Yamagata, K., Fujimoto, S., Tsuruya, K., Narita, I., Kasahara, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71301-6 · Cited by 26
Approximate Mortality Risks between Hyperuricemia and Diabetes in the United States
Chen, P.-H., Chen, Y.-W., Liu, W.-J., Hsu, S., Chen, C., & Lee, C.-L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122127 · Cited by 18
Song, Y., Zhang, X., Zhang, H., Yang, Q., Zhang, S., Zhang, Y., Chen, Y., Ji, Y., & Hu, X. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0655-x · Cited by 17
Self-citation
Metadata
- Authors
- Zhang, M., Zhu, X., Wu, J., Huang, Z., Zhao, Z., Zhang, X., Xue, Y., Wan, W., Li, C., Zhang, W., Wang, L., Zhou, M., Zou, H., & Wang, L.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-02-07
- Volume
- 12
- Pages
- 791983-791983
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4226218623
- Cited by
- 367
- References
- 30
- FWCI
- 40.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.